ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2020
Preclinical PERCIST and 25% of SUV
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer.European journal of nuclear medicine and molecular imaging · 2022Trial
- The application of liver cancer organoids in tumour precision medicine: A comprehensive review.iLIVER · 2025Review
- Reproducibility and repeatability of 18F-(2S, 4R)-4-fluoroglutamine PET imaging in preclinical oncology models.PloS one · 2025Article
- Patient-Derived-Xenografts in Mice: A Preclinical Platform for Cancer Research.Cold Spring Harbor perspectives in medicine · 2024Review
- Deep learning generation of preclinical positron emission tomography (PET) images from low-count PET with task-based performance assessment.Medical physics · 2024Article
- The National Cancer Institute's Co-Clinical Quantitative Imaging Research Resources for Precision Medicine in Preclinical and Clinical Settings.Tomography (Ann Arbor, Mich.) · 2023Review
- Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials.Tomography (Ann Arbor, Mich.) · 2023Review
- Demystifying Supervised Learning in Healthcare 4.0: A New Reality of Transforming Diagnostic Medicine.Diagnostics (Basel, Switzerland) · 2022Review
- Harnessing preclinical models for the interrogation of ovarian cancer.Journal of experimental & clinical cancer research : CR · 2022Review
- Deep Learning and Transfer Learning for Malaria Detection.Computational intelligence and neuroscience · 2022Article
- In vivo quantitative assessment of therapeutic response to bortezomib therapy in disseminated animal models of multiple myeloma with [EJNMMI research · 2021Article
- Research Progress, Challenges, and Breakthroughs of Organoids as Disease Models.Frontiers in cell and developmental biology · 2021Review
- Article
- Co-Clinical Imaging Resource Program (CIRP): Bridging the Translational Divide to Advance Precision Medicine.Tomography (Ann Arbor, Mich.) · 2020Article
Corrections and comments
- Commented on bySUV2020
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
Numerous recent works highlight the limited utility of established tumor cell lines in recapitulating the heterogeneity of tumors in patients. More realistic preclinical cancer models are thought to be provided by transplantable, patient-derived xenografts (PDXs). The inter- and intratumor heterogeneity of PDXs, however, presents several challenges in developing optimal quantitative pipelines to assess response to therapy. The objective of this work was to develop and optimize image metrics for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.